Latest Us Army News

Environmental Clean Technologies has secured A$10.6 million in a placement to fast-track commercialisation of its Flash Joule Heating platform and MXene manufacturing, backed by a strategic acquisition and feedstock supply.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

Ioneer Ltd continues to build momentum on its Rhyolite Ridge lithium-boron project, signing strategic MOUs with Korean partners and navigating a legal appeal while preparing for construction.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Electro Optic Systems (ASX:EOS) posted a 284% surge in first-half 2026 revenue to $169 million, driven by robust defence contracts and regional tensions. Its order book hit a historic $846 million, prompting an upgrade to full-year guidance and signalling strong momentum in counter-drone and laser weapon systems.

Elsight Limited (ASX:ELS) has shattered its revenue records in H1 2026, delivering a nearly fourfold increase over the prior year alongside expanding US defence contracts and new product launches.

IperionX has won up to US$6.6 million from the US Department of War to scale production of ballistic-grade titanium plate and military components, aiming to reduce reliance on imports and strengthen domestic supply chains.

Environmental Clean Technologies (ASX: ECT) has submitted detailed data to the US EPA showcasing its Rapid Electrothermal Mineralisation (REM) technology's ability to destroy PFAS with over 99% efficacy and full fluorine mass balance, aiming to meet stringent regulatory standards.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.

Environmental Clean Technologies (ASX: ECT) has completed a pilot Rapid Electrothermal Mineralisation system that delivers 18 times the power of its lab prototype, enabling additive-free, in-situ PFAS destruction and targeting a field demonstration in H2 2026.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.